Lilly/Incyte's JAK inhibitor needs RA Phase III to compare with Pfizer's tofacitinib
13:20 EDT 11 Jun 2012 | SCRIP
Lilly and Incyte have reported positive 12-week data from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available Janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis.....
Original Article: Lilly/Incyte's JAK inhibitor needs RA Phase III to compare with Pfizer's tofacitinib
More From BioPortfolio on "Lilly/Incyte's JAK inhibitor needs RA Phase III to compare with Pfizer's tofacitinib"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
